Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...
( NewsNation) — Shares in some pharmaceutical and biotechnology companies, including those that manufacture vaccines, fell ...
So an annual COVID booster is not considered enough for some more vulnerable people. For adults aged 65 to 74 , a booster is ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
BofA Securities cuts Moderna's price target from $110 to $90 due to vaccine sales concerns. Moderna faces tough ...
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Shares of several COVID-19 vaccine developers sank fast enough to reflect investor jitters about vaccine policy given RFK’s ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback